Celgene Corporation (CELG) is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $79.98, down from yesterday’s close by -1.70%. Given the stock’s recent action, it seemed like a good time to take a closer look at the company’s recent data.Fundamental Analysis
Celgene Corporation (CELG) currently trades with a market capitalization of $59.85 Billion. That value represents a market adjusting for revenues that have been growing by 19.45 % on a quarterly year/year basis as of the company’s last quarterly report.
You can get a sense of how sustainable that is by a levered free cash flow of $3.77 Billion over the past twelve months. Generally speaking, earnings are expected to grow in coming quarters. Analysts are forecasting earnings of $1.96 on a per share basis this quarter. Perhaps, that suggests something about why 0.49% of the outstanding share supply is held by institutional investors.
No analysis is ever complete without a thorough survey of a stock’s technical behavior. Looking at the stock’s movement on the chart, Celgene Corporation recorded a 52-week high of $147.17. It is now trading 67.19% off that level. The stock is trading $87.87 its 50-day moving average by 7.89%. The stock carved out a 52-week low down at $81.05.
In recent action, Celgene Corporation (CELG) has made a move of -10.76% over the past month, which has come on Strong relative transaction volume. Over the trailing year, the stock is underperforming the S&P 500 by 15.08, and it’s gotten there by action that has been more volatile on a day-to-day basis than most other stocks on the exchange. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 1.91% with $723.90 Million sitting short, betting on future declines. That suggests something of the likelihood of a short squeeze in shares of CELG.